Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 9/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22786993 | 0.81 | KCNN4 (0.47) | SMN1; SMN2HIF1ANPSR1RXFP1HTR2C | |
| SCHEMBL30147353 | 0.78 | HSD11B1 (0.61) | SMN1; SMN2KCNN4ALDH1A1LMNAP2RX7 | |
| SCHEMBL20684736 | 0.78 | KCNN4 (0.54) | SMN1; SMN2HIF1ANPSR1RXFP1HTR2C | |
| SCHEMBL3051119 | 0.77 | P2RX7 (0.46) | HTR2CKCNN4ALDH1A1P2RX7 | |
| SCHEMBL12748014 | 0.76 | AGTR1 (0.46) | SMN1; SMN2HIF1ANPSR1RXFP1HTR2C | |
| SCHEMBL21091600 | 0.75 | KCNN4 (0.57) | KCNN4ALDH1A1P2RX7 | |
| SCHEMBL13491996 | 0.75 | HIF1A (0.41) | SMN1; SMN2HIF1ANPSR1RXFP1HTR2C | |
| SCHEMBL3784925 | 0.74 | KCNN4 (0.51) | SMN1; SMN2HIF1ANPSR1RXFP1HTR2C | |
| SCHEMBL7211222 | 0.74 | LMNA (0.44) | SMN1; SMN2HIF1ANPSR1RXFP1HTR2C | |
| SCHEMBL9822769 | 0.74 | HIF1A (0.46) | SMN1; SMN2HIF1ANPSR1RXFP1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| EP-2207773-A2 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009057811-A2 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-05-07 | — | — | WO | disclosed |
| US-6211219-B1 | DRUGS, ANALGESICS AND AGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2001-04-03 | — | — | US | disclosed |
| US-6150391-A | Diazabicyclo-octane derivatives as 5-HT receptor ligands | MERCK SHARP & DOHME LTD. | 2000-11-21 | — | — | US | disclosed |
| US-6140347-A | Azetidine, pyrrolidine and piperidine derivatives as 5-HT receptor agonists | MERCK SHARP & DOHME LTD. (GB) | 2000-10-31 | — | — | US | disclosed |
| US-6107321-A | Diazabicyclooctane derivatives having selective 5-HT1Dalpha agonist activity | MERCK SHARP & DOHME LTD. (GB) | 2000-08-22 | — | — | US | disclosed |
| US-6054469-A | Substituted tetrahydropyridine derivatives acting on 5-HT receptors | MERCK SHARP & DOHME LTD. (GB) | 2000-04-25 | — | — | US | disclosed |
| US-6051591-A | Diazabicyclooctane derivatives | MERCK SHARP & DOHME LTD. (GB) | 2000-04-18 | — | — | US | disclosed |
| WO-1997028162-A1 | DIAZABICYCLO-OCTANE DERIVATIVES AS 5-HT RECEPTOR LIGANDS | MERCK SHARP & DOHME LIMITED (GB) | 1997-08-07 | — | — | WO | disclosed |
| WO-1997019073-A1 | PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-29 | — | — | WO | disclosed |
| WO-1997018202-A1 | SUBSTITUTED PIPERIDINE DERIVATIVES AS SELECTIVE AGONISTS OF 5-HT RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-22 | — | — | WO | disclosed |
| WO-1997018204-A1 | SUBSTITUTED TETRAHYDROPYRIDINE DERIVATIVES ACTING ON 5-HT RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-22 | — | — | WO | disclosed |
| WO-1997018203-A1 | PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-22 | — | — | WO | disclosed |
| WO-1997016446-A1 | BICYCLIC HETEROARYL-ALKYLENE-(HOMO)PIPERAZINONES AND THIONE ANALOGUES THEREOF, THEIR PREPARATION AND THEIR USE AS SELECTIVE AGONISTS OF 5-HT1-LIKE RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-09 | — | — | WO | disclosed |
| WO-1997011945-A1 | DIAZABICYCLOOCTANE DERIVATIVES HAVING SELECTIVE 5-HT1DALPHA ANTAGONIST ACTIVITY | MERCK SHARP & DOHME LIMITED (GB) | 1997-04-03 | — | — | WO | disclosed |
| WO-1997011949-A1 | DIAZABICYCLOOCTANE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1997-04-03 | — | — | WO | disclosed |
| EP-0759918-A1 | PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES OF INDOL-3-YLALKYL AS 5-HT1D-ALPHA AGONISTS | MERCK SHARP & DOHME LTD. (GB) | 1997-03-05 | — | — | EP | disclosed |
| WO-1995032196-A1 | PIPERAZINE, PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES OF INDOL-3-YLALKYL AS 5-HT1D-ALPHA AGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1995-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | COL1A1, COL2A1, COL14A1 | SMN1; SMN2 3814/4885HIF1A 149/4885NPSR1 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.